



R&D DAY

Wednesday, October 7, 2015

8:30am-10:00am

Registration/Breakfast at 8:00 am

Omni Berkshire Place

21 East 52nd Street

Aquinox's lead drug candidate, AQX- 1125, is an oral, once daily, small molecule activator of SHIP1 currently in Phase 2 development for the treatment of Interstitial Cystitis, also known as Bladder Pain Syndrome.

For more information or to RSVP please contact Bill Kadel at bkadel@troutgroup.com